Open an account

Pasithea Therapeutics

KTTA · NASDAQ

$0.41−$0.0023 (−0.56%)TodayMarket closed ·
Prev close $0.4123

About KTTA

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 5 full-time employees. The company went IPO on 2021-08-13. The firm is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Employees
4
Headquarters
Miami Beach, Florida
Listed
Aug 13, 2021
Sector
Health Care
Industry
Biotechnology
Website
pasithea.com

KTTA key statistics

Market cap
13.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
111.28K
Volume
37.50K
Open price
$0.4184
High today
$0.4151
Low today
$0.41
52 Week high
$2.06
52 Week low
$0.281

Pasithea Therapeutics (KTTA) at a glance

As of Oct 20, 2026, Pasithea Therapeutics (KTTA) shares are priced at $0.41, giving the company a market cap of 13.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.41 and $0.4151. The current price is 0.0% above the day's low and 1.2% below its high.

Volume so far is 37.50K shares, below the average of 111.28K shares a day.

Over the past year Pasithea Therapeutics has ranged from $0.281 to $2.06, and now sits 7% of the way up that range.

Pasithea Therapeutics met or beat analyst EPS estimates in 3 of the last 6 quarters. In Q2 FY26 it reported -$0.16 per share against an estimate of -$0.1632.

The average analyst price target is $3.06, 646.3% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $3.06
Low
$3.03
Now
$0.41
High
$3.15

KTTA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 6 quarters, by 137.0% on average.

  1. Q4 FY21: reported $2.40 per share against an estimate of -$1.02
  2. Q1 FY22: reported -$1.40 per share against an estimate of -$0.408
  3. Q4 FY24: reported -$2.41 per share against an estimate of $0.00
  4. Q4 FY25: reported -$0.79 per share against an estimate of -$0.1836
  5. Q1 FY26: reported -$0.12 per share against an estimate of -$0.459
  6. Q2 FY26: reported -$0.16 per share against an estimate of -$0.1632

KTTA news

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Avi Kapoor

    Crude Oil Gains 1%; Tilray Brands Shares Plunge

  • Avi Kapoor

    Nasdaq Rises 100 Points; Chagee Shares Gain After Q3 Results

  • Henry Khederian

    Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today

  • Avi Kapoor

    Nasdaq Jumps Over 100 Points; Deere Shares Fall After Q4 Results

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Avi Kapoor

    Nasdaq Gains Over 100 Points; US Consumer Sentiment Rises In November

Similar companies

Companies in the same industry as Pasithea Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.